American Cancer Society, Guardant Health Partner to Expand Cancer Screening Access

American Cancer Society and Guardant Health Forge Strategic Partnership to Expand Cancer Screening and Tackle Health Disparities Nationwide The American Cancer Society has announced a strategic partnership with Guardant Health , a leading precision oncology company, to improve access to…

Read MoreAmerican Cancer Society, Guardant Health Partner to Expand Cancer Screening Access
Exicure Completes Final Patient Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma

Exicure Completes Final Patient Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma

Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in…

Read MoreExicure Completes Final Patient Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma